PPARG and hepatocellular carcinoma: Simvastatin can inhibit the proliferation of HCC cells by inhibiting PKM2-mediated glycolysis, inhibiting the HIF-1α/PPAR-γ/PKM2 axis, and increasing the sensitivity of HCC cells to sorafenib [159].